HLA‐matched allogeneic anti‐CD19 CAR‐T therapy in treating a relapsed/refractory acute lymphoblastic leukemia patient with high tumor burden

Abstract

The genetically engineered chimeric antigen receptor T cell (CAR-T) therapy has shown remarkable clinical efficacy in the treatment of hematological malignancies. Nonetheless, it is difficult to harvest adequate autologous T cells to manufacture potent CAR-T cell products in patients with high tumor burden and prior tumor-reductive treatment. Here we reported a relapsed/refractory acute lymphoblastic leukemia patient with high leukemia burden and central nervous system (CNS) involvement. The patient responded to donor-derived HLA-matched allogeneic CAR-T treatment, with the achievement of quick complete remission. And for the first time, we revealed the development of a cerebral CRS in situ after allogeneic CAR-T therapy. K E Y W O R D Sacute lymphoblastic leukemia, allogeneic chimeric antigen receptor T cells, central nervous system leukemia, cytokine release syndrome, HLA-matched INTRODUCTIONChimeric antigen receptor T cell (CAR-T) therapy, a newly established adoptive T cell therapy, specifically redirects genetically modified immune cells to fight against hematologic malignancies. According to recent clinical trials, CAR-T therapy has a complete remissionThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.